Mountain Crest V announces non-binding term sheet to combine with CUBEBIO at $620M pre-money value

Mountain Crest Acquisition Corp. V

Pre-transaction equity value of CUBEBIO set at $620 million, subject to adjustment.
CUBEBIO is a Korea-based cancer diagnostics company using urine-based technology.
Non-binding term sheet dated April 26, 2024; definitive merger agreement yet to be signed.
Mountain Crest V is a SPAC; has completed four prior business combinations.
Global Fund LLC engaged as advisor to CUBEBIO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.